Dr. Jagadeesh Rao, IGC Pharma LLC, United States.
Dr. Jagadeesh S. Rao is a distinguished neuroscientist and clinical researcher with over 15 years of experience in neuroscience, psychiatry, neuropharmacology, and drug development. His career is marked by significant contributions to the understanding and treatment of neurodegenerative diseases, especially Alzheimer’s disease. With a strong academic foundation in molecular biology and biochemistry, Dr. Rao has led groundbreaking work in clinical trial design, preclinical toxicology, and regulatory submissions, including IND and CMC documentation for FDA approvals. He currently serves as Principal Scientist at IGC Pharma Inc., where he leads teams in Phase I and II clinical trials, manages CROs and budgets, and has developed both OTC and investigational drug products.
Profile
Orcid
🧠 Early Academic Pursuits
Dr. Jagadeesh S. Rao began his scientific journey with a deep interest in the complexities of the human brain and molecular biology. From the early stages of his academic training, he demonstrated exceptional dedication to exploring the interplay between neurobiology, biochemistry, and psychiatric health. His pursuit of a Ph.D. laid a robust foundation in neuroscience and neuropharmacology, equipping him with a multidisciplinary understanding of the cellular and molecular mechanisms that underlie neurodegenerative and neuropsychiatric disorders. This strong academic grounding would later become the driving force behind his innovative contributions to research in pain, Alzheimer’s disease, and drug development.
🧪 Professional Endeavors in Neuroscience and Drug Development
With over 15 years of professional experience, Dr. Rao has successfully navigated and led multiple domains including toxicology, psychiatry, and molecular biology. Currently serving as a Principal Scientist at IGC Pharma Inc., he has taken a prominent role in advancing clinical drug development, particularly in designing and executing Phase I and II trials. His expertise extends to critical regulatory processes such as Investigational New Drug (IND) submissions, clinical protocol design, and Chemistry, Manufacturing, and Controls (CMC). He has actively led teams in drug formulation, batch production, validation, and compliance with FDA and ISO standards—demonstrating a blend of scientific acumen and regulatory insight.
🧬 Contributions and Research Focus in Neuropharmacology
Dr. Rao’s research centers on developing therapeutic interventions for neurodegenerative and neuropsychiatric conditions, especially Alzheimer’s disease. His contributions span the full spectrum of drug development: from preclinical toxicology and pharmacokinetics to clinical pharmacodynamics and regulatory documentation. He has designed preclinical studies adhering to GLP standards, involving mutagenesis assays, reproductive and general toxicity assessments, and immunogenicity tests. Moreover, he played a key role in the development of over-the-counter (OTC) pain relief cream products, contributing both to academic research and commercial innovation. His insights into P450 enzyme polymorphisms and their effects on drug metabolism showcase a precision medicine approach to pharmacological care.
🏅 Accolades and Recognition in Clinical Research
While much of Dr. Rao’s work has been behind the scenes of scientific advancement and regulatory excellence, his leadership in preparing CMC documents and overseeing investigational drug submissions has earned him widespread respect among peers. His oversight of departmental budgets and his management of Clinical Research Organizations (CROs) reflect not only scientific brilliance but also strategic and financial stewardship in clinical drug development. The successful initiation of Phase I and II clinical trials under his guidance stands as a testament to his expertise and diligence in the field.
🌍 Impact and Influence in Translational Medicine
Dr. Rao’s work bridges the gap between laboratory research and clinical application. His projects have advanced the translational medicine field by offering therapeutic candidates that move seamlessly from preclinical safety assessments to human trials. His influence is felt not only through the innovative drugs developed under his watch but also in shaping protocols that align with FDA’s stringent regulatory frameworks. His understanding of the molecular intricacies of neuropsychiatric diseases allows him to propose and test interventions that directly respond to the unmet needs of patients and healthcare systems alike.
🔬 Legacy in Scientific Rigor and Innovation
One of Dr. Rao’s enduring legacies lies in his rigorous approach to clinical pharmacology and his commitment to quality and safety in every phase of drug development. His ability to interpret complex PK/PD data, assess drug-drug interactions, and foresee adverse events has significantly shaped safer and more effective drug protocols. He has also contributed to the creation of technical documentation and risk assessments that serve as gold standards in the field, ensuring compliance and reproducibility for future scientists and clinicians.
🚀 Future Contributions and Vision for Neurotherapeutics
Looking ahead, Dr. Rao continues to pave the way in neurotherapeutics with a focused ambition to develop treatments for cognitive and behavioral disorders rooted in neuroinflammation and synaptic dysfunction. His vision includes refining clinical strategies using personalized medicine models and leveraging his expertise in biochemistry and molecular neuropharmacology. As the global demand for effective neurological therapies increases, Dr. Rao’s evolving research and leadership promise to yield transformative solutions that will benefit countless patients worldwide.
Publication
1. Title: Neurobiological alteration in agitation in Alzheimer’s disease and possible interventions
Author(s): Rao, Jagadeesh S.; Tangarife, Maria Alejandra; Mukunda, Ram
Year: 2024
2. Title: Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain
Author(s): Kim, Hyung-Wook; Cheon, Yewon; Modi, Hiren R.; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2012
3. Title: Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients
Author(s): Rao, J. S.; Keleshian, V. L.; Klein, S.; Rapoport, S. I.
Year: 2012
4. Title: Gabapentin’s minimal action on markers of rat brain arachidonic acid metabolism agrees with its inefficacy against bipolar disorder
Author(s): Reese, Edmund A.; Cheon, Yewon; Ramadan, Epolia; Kim, Hyung-Wook; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.; Taha, Ameer Y.
Year: 2012
5. Title: Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder
Author(s): Ramadan, Epolia; Basselin, Mireille; Rao, Jagadeesh S.; Chang, Lisa; Chen, Mei; Ma, Kaizong; Rapoport, Stanley I.
Year: 2012
6. Title: Altered Expression of G-protein subunits and GRKs in Alzheimer’s Disease
Author(s): Reese, Edmund A.; Kim, Hyung-Wook; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2011
7. Title: Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain
Author(s): Cheon, Yewon; Park, Jee-Young; Modi, Hiren R.; Kim, Hyung-Wook; Lee, Ho-Joo; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.
Year: 2011
8. Title: Dietary n-6 PUFA deprivation downregulates arachidonate but upregulates docosahexaenoate metabolizing enzymes in rat brain
Author(s): Kim, Hyung-Wook; Rao, Jagadeesh S.; Rapoport, Stanley I.; Igarashi, Miki
Year: 2011
9. Title: Disturbed Choline Plasmalogen and Phospholipid Fatty Acid Concentrations in Alzheimer’s Disease Prefrontal Cortex
Author(s): Igarashi, Miki; Ma, Kaizong; Gao, Fei; Kim, Hyung-Wook; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2011
10. Title: Olanzapine Decreases Brain Arachidonic Acid (AA) Metabolism in Rats by Reducing Plasma Availability of AA
Author(s): Cheon, Yewon; Modi, Hiren R.; Park, Jee-Young; Kim, Hyung-Wook; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.
Year: 2011
✅Conclusion
Dr. Rao’s career reflects a powerful blend of scientific innovation, regulatory excellence, and clinical insight. His dedication to developing safe and effective neurological therapeutics has significantly advanced the field of translational medicine. As a leader, mentor, and researcher, his ongoing work continues to influence modern approaches to treating complex brain disorders, setting a high standard for future neuropharmacological research and therapeutic innovation.